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Summary In order to evaluate the potential clinical and economic benefits of granulocyte colony-stimulating factor (G-CSF, filgrastim)
following peripheral blood progenitor cells (PBPC) rescue after high-dose chemotherapy (HDCT), 23 consecutive patients aged less than
60 years with poor-prognosis, high-grade non-Hodgkin's lymphoma (NHL) were entered into a prospective randomized trial between May
1993 and September 1995. Patients were randomized to receive either PBPC alone (n = 12) or PBPC+G-CSF (n = 11) after HDCT with
busulphan and cyclophosphamide. G-CSF (300 gg day-') was given from day +5 until recovery of granulocyte count to greater than
1.0 x 1091-1 for 2 consecutive days. The mean time to achieve a granulocyte count > 0.5 x 1091-1 was significantly shorter in the G-CSF arm
(9.7 vs 13.2 days; P<0.0001) as was the median duration of hospital stay (12 vs 15 days; P= 0.001). In addition the recovery periods (range
9-12 vs 11-17 days to achieve a count of 1.0 x 1091-1) and hospital stays (range 11-14 vs 13-22 days) were significantly less variable in
patients receiving G-CSF in whom the values clustered around the median. There were no statistically significant differences between the
study arms in terms of days of fever, documented episodes of bacteraemia, antimicrobial drug usage and platelet/red cell transfusion
requirements. Taking into account the costs of total occupied-bed days, drugs, growth factor usage and haematological support, the mean
expenditure per inpatient stay was £6500 (range £5465-£8101) in the G-CSF group compared with £8316 (range £5953-£15801) in the
group not receiving G-CSF, with an observed mean saving of £1816 per patient (or 22% of the total cost) in the G-CSF group. This study
suggests that after HDCT and PBPC rescue, the use of G-CSF leads to more rapid haematological recovery periods and is associated with a
more predictable and shorter hospital stay. Furthermore, and despite the additional costs for G-CSF, these clinical benefits are not translated
into increased health care expenditure.
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Severe and sometimes prolonged myelosuppression is a major
complication of high-dose chemotherapy (HDCT). During this
period, patients are at great risk of developing life-threatening
bacterial infections, a risk that is proportional to the degree and
duration of granulocytopenia (Bodey et al, 1966). Re-infusion of
autologous bone marrow has been used to reduce the duration of
pancytopenia and this, together with improvements in supportive
care, has combined to make HDCT a treatment with acceptable
levels ofmorbidity and mortality. More recently, ithas been shown
that peripheral blood progenitor cells (PBPC) produce more rapid
haematological recovery than autologous bone marrow (Sheridan
et al, 1992; Beyer et al, 1995; Schmitz et al, 1996). The potential
benefits ofusing haematopoietic growth factors to accelerate gran-
ulocyte recovery after bone marrow or PBPC rescue have also
been explored. In most studies with autologous bone marrow, the
administration of haematopoietic growth factors was associated
with accelerated granulocyte recovery, fewer febrile days, reduced
antibiotic administration and shorter hospital stays (Sheridan
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et al, 1989; Nemunaitis et al, 1991; Link et al, 1992; Linch et al,
1993; Gisselbrecht et al, 1994; Stahel et al, 1994). However, in
contrast to autologous bone marrow rescue, the benefits associated
with the usage of growth factors in the period after PBPC rescue
following HDCT remain to be established. For these reasons, a
prospective, randomized trial of G-CSF (filgrastim) in patients
with poor-prognosis high-grade non-Hodgkin's lymphoma (NHL)
receiving PBPC rescue following HDCT was performed.
PATIENTS AND METHODS
Between May 1993 and September 1995, 24 consecutive patients
aged less than 60 years with poor-prognosis high-grade NHL were
entered into a prospective randomized trial. Twenty-two patients
had high-grade NHL (Kiel classification) with two or three
adverse features (stage III or IV disease, raised serum lactate
dehydrogenase level and Karnofsky performance status < 70), as
defined by the international NHL prognostic index (1993), one
patient had lymphoblastic NHL and onepatient Burkitt-type NHL.
The study protocol was approved by the local medical research
ethics committee, and all patients gave written informed consent
for entry into the trial. One case was randomized incorrectly
before receiving chemotherapy; this individual died during
chemotherapy and has not been considered further in this report.
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Treatment, PBPC collections, HDCT and PBPC
reinfusion
Patients received seven weekly cycles ofVAPEC-B chemotherapy
according to the dose and schedule described previously
(Pettengell et al, 1996). On the day afterthe last dose oforal etopo-
side at week 7, they commenced G-CSF (filgrastim 300 ,ug d-l or
5 gg kg-' ifbody weight > 70 kg, Amgen, Cambridge, UK) given
by daily subcutaneous injection. Leukapheresis was performed on
the day of anticipated maximum PBPC release and the cells were
cryopreserved. After this, three cycles of consolidation chemo-
therapy with ifosfamide (3 g m-2) and cytarabine (800 mg m-2)
were given as described previously (Pettengell et al, 1996). HDCT
consisted of oral busulphan 4 mg kg-1 day-' orally in divided
doses for 4 days as an outpatient, followed by cyclophosphamide
50 mg kg-' day-1 with intravenous mesna for 4 days. The PBPC
were reinfused intravenously 48 h after the last dose ofcyclophos-
phamide. On admission to the transplant unit, patients were
randomized to receive either PBPC rescue alone or PBPC rescue
followed by G-CSF. Patients randomized to receive G-CSF were
given filgrastim 300 jig d-l subcutaneously starting on day 5 after
PBPC reinfusion, and this was continued until the granulocyte
count was > lx109 cells 1-1 for 2 successive days.
Supportive measures
Prophylactic medication, including oral cotrimoxazole, flucona-
zole and acyclovir, was given to all patients. After HDCT, a full
blood count and differential were measured daily until the granu-
locyte count was > 1.0 x 109 1-1 for 2 consecutive days. As soon as
fever equal or greater than 38.0°C occurred, blood cultures were
taken and empiric i.v. antibiotic treatment was initiated. Packed
red blood cells and donor platelet tranfusions were used to main-
tain a haemoglobin > 9 g 1-1 and platelets 2 20 x 109 1-1, and all
blood products were irradiated to 25 Gy. Patients who were
cytomegalovirus (CMV) negative received blood products from
CMV-negative donors. If a patient randomized to receive PBPC
rescue alone (i.e without G-CSF) had a granulocyte count < 1.0 x
109 1-1 by day 15, they were commenced on G-CSF 300jig daily
for 5 days. Patients were discharged from hospital when they were
clinically well, had been apyrexial and off i.v. antibiotics for 24 h
and had a granulocyte count > 1.0 x 109 1-'.
Cost analysis
For each patient, costs were collected for blood product require-
ments, antimicrobial drugs, G-CSF (if appropriate) and every
occupied-bed day for time spent in the transplant unit starting from
the day of reinfusion of PBPC to the day of discharge. The calcu-
lated unit cost of an occupied-bed day was £395, a figure derived
from hotel, nursing and medical staff costs incurred at the institute.
The total costs for each patient were found by summing the number
of resources consumed multiplied by their respective unit prices.
Charges for initial and high-dose chemotherapy, leukapheresis,
cryopreservation, routine haematological, biochemical and micro-
biological investigations werenotincluded in the economicanalyses.
Statistical analysis
While a daily full blood count and differential had been planned,
this was not always strictly adhered to. In order to estimate
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aOne patient had lymphoblastic NHL and one patient Burkitt-type NHL.
recovery times, the individual granulocyte profiles were all plotted
and the timing of recovery to 0.5 x 109 1-1 and 1.0 x 109 1-' were
reasonably estimated using linear interpolation on a log scale.
Comparisons between mean values in the two arms of the trial
were made with t-tests (in which the variance in each group was
permitted to differ), between median values with Mann-Whitney
U-tests and between variances with F-tests.
RESULTS
Patients
The pretreatment characteristics of the 23 patients studied are
summarized in Table 1. Elevenpatients were randomized to receive
G-CSF and 12 to receive no G-CSF (control group). In the control
group, three patients were treated with growth factors before day
15; two patients received G-CSF (onepatient because ofprolonged
granulocytopenia and the otherpatientbecause ofprolonged granu-
locytopenia and resistant pyrexia) and one patient received granu-
locyte-macrophage colony-stimulating factor (GM-CSF) (because
of resistant pyrexia with pulmonary candidiasis). These three
patients were analysed on an 'intention to treat' basis (i.e. as part of
the control group), although they had actually received growth
factors. Graft data were available from all the patients, and there
was no difference in the graft obtained from the two groups; these
contained a median of 7.3 x 106 CD34 cells kg-' in the G-CSF
groupand7.7 x 106CD34cellskg-' inthecontrolgroup (seeTable 1).
Haemopoietic recovery
Figure 1 shows the time to granulocyte recovery forboth treatment
groups. The mean number of days to a granulocyte count of






















Figure 1 Time to granulocyte recovery (0.5x109 I-') after HDCT and PBPC
re-infusion. Three patients in the control group who were given G-CSF/GM-
CSF are represented by +. Horizontal bars represent mean values
0.5 x 109 1- or more was significantly less in patients randomized
to receive G-CSF [9.7 (9-11) days] than in those not receiving
G-CSF [13.2 (10-16) days, P < 0.0001]. The estimated mean
reduction was 3.5 days with a 95% CI of 2.2-4.8 days. Similar
results were seen for the mean number of days to a granulocyte
count of 1.0 x 109 1-1 in the patients receiving G-CSF [10.1 (9-12)
days] compared with patients not receiving G-CSF [14.7 (11-17)
days, P < 0.0001]. The estimated mean reduction was 4.6 days with
a 95% CI of 3.1-6.1 days. Patients receiving G-CSF also exhibited
significantly less variation about the mean value (P = 0.002, F-test),
suggesting a more consistent time to engraftment compared with
the control patients not receiving G-CSF (see Figure 1). Of the
three patients in the control group who received G-CSF/GM-CSF
(represented by crosses in Figure 1), two demonstrated the earliest
recovery in their group, while the third was the last to recover.
No difference was seen between the two groups of patients
before discharge in terms of the time to an unsupported platelet
count .20 x 109 1-' orthe numberofplatelettransfusions. A median
number of 12 units of platelets was required by both the G-CSF
group (range 4-30 units) and the control group (range 4-76 units).
There was also no significant difference in the median number of
units ofred blood cells transfused; this was 4 units (range 2-5) in
the G-CSF group and 5 units (range 0-9) in the control group (see
Table 2).
Clinical outcome and hospital stay
No statistically significant differences were observed between the
two groups in terms of the number of febrile days or days on
antibiotics, antifungal or antiviral therapy, although, overall, the
G-CSF group appears to be associated with shorter periods of
antimicrobial therapy (see Table 2). No significant difference was
seen in the number of positive blood cultures, although 50% of
patients in the control group and 27% in the G-CSF group had
positive blood cultures during the periods of pyrexia. However,
patients receiving G-CSF were discharged from hospital signifi-
cantly earlier [12 (11-14) days after PBSC reinfusion] than
patients not receiving G-CSF [15 (13-22) days] (P = 0.001, see
Table 2). In addition, as shown in Figure 2, the range of days in
hospital was much narrower in the G-CSF group.
Cost benefit analysis
In order to evaluate the cost-effectiveness of using G-CSF, the
total costs of every occupied-bed day, which included the costs of
nursing and medical staffing, anti-microbial drug usage, blood
product requirement and G-CSF usage for each patient in both
groups, were analysed. As can be seen from Table 3, there was an
observed saving per patient for every item, excepting the cost of
the G-CSF itself, most notably with regard to the occupied-bed
days' costs where there was an average saving of£1373. The total
costs are shown in Figure 3, from which it is apparent that there is
an outlier in terms of cost in the control group. On omitting this
unusual case, the average saving per patient in the G-CSF group
compared with the control group was £1136 with 95% CI
(-£83-£2356). Even if a conservative view ofthe data is adopted,
it is unlikely that giving G-CSF will increase the cost per patient
by more than £83 (lower 95% confidence limit) and, for the cases
in this particular study, there was an observed saving of£1816 per
patient or 22% ofthe total cost.
DISCUSSION
The major benefits ofreinfusing PBPC instead ofautologous bone
marrow after HDCT include an improved rate ofplatelet and gran-
ulocyte recovery, reduced number of platelet transfusions and
significantly earlier discharge from hospital (Sheridan et al, 1992;
Table 2 Clinical outcome
PBPC + G-CSF PBPC alone
Median (range) Median (range) P-value
Febrile days > 380C 3 (1-7) 4 (1-14) 0.37
Days on i.v. antibioticsa 28 (21-37) 36 (0-61) 0.06
Days on i.v. antifungalsa 12 (0-13) 14 (0-21) 0.29
Days on i.v. antiviral 12 (4-14) 12.5 (3-18) 0.71
Units of platelet concentrates 12 (4-30) 12 (4-76) 0.44
Units of RBC concentrates 4 (2-5) 5 (0-9) 0.19
Days until discharge 12 (11-14) 15 (13-22) 0.001
aSum of the total number of days of each antimicrobial prescribed.
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Figure 2 Time to discharge from hospital after PBPC re-infusion. Three
patients in the control group who were given G-CSF/GM-CSF are
represented by +. Horizontal bars represent median values
Beyer et al, 1995; Schmitz et al, 1996). These advantages appear
to translate into a substantial reduction ofcosts, with an economic
analysis in one study demonstrating an approximate cost-saving of
30% per patient (Smith et al, 1995). In an effort to further reduce
the number of days in hospital and treatment-related complica-
tions, haemopoietic growth factors are now frequently being used
after PBPC rescue. Cortelazzo et al (1995) found that, in a cohort
of40 patients with high-grade NHL, administration ofG-CSF was
not associated with any difference in terms of granulocyte or
platelet engraftment, tranfusion requirements, number of febrile
days, antibiotic requirements or days of hospitalization compared
with patients not receiving G-CSF. However, Spitzer et al (1994)
in a randomized study evaluating 37 patients with a variety of
solid malignancies found that administration of G-CSF plus GM-
GSF was associated with significantly faster granulocyte recovery
and reduced duration of hospitalization; no difference was
reported in the number of septic episodes, the number of febrile
days or the rate of platelet recovery. Klumpp et al (1995) in a
Figure 3 Overall cost (see text for definition). Three patients in the control
group who were given G-CSF/GM-CSF are represented by +. Solid
horizontal bars represent mean values and the dashed horizontal bar
represents the mean value after omitting the outlier
randomized series of41 patients found that G-CSF administration
resulted in significant improvement in granulocyte recovery,
reduced duration of hospitalization and intravenous antibiotic
therapy. Colombat et al (1996) reported that the administration of
GM-CSF was associated with improved time to granulocyte
recovery, reduced febrile days, reduced antibiotics therapy and
fewer days in hospital. More recently, Linch et al (1995) and
McQuaker et al (1997) in randomized studies of63 patients and 38
patients, respectively, found that patients receiving G-CSF
achieved a significantly faster granulocyte engraftment time and
spent significantly less time in hospital. A retrospective analysis
by Dunlop et al (1994) found administration of high-dose
(10 gg kg-') G-CSF was associated with an increased cost,
whereas McQuaker et al (1997) found a cost-saving of £1000 per
patient receiving low-dose (50 gg m-2) G-CSF.
In the present study, the administration of G-CSF after HDCT
and PBPC re-infusion was associated with a statistically signifi-
cant reduction in mean time to granulocyte recovery. The mean
Table 3 Cost analysis
PBPC + G-CSF (1) PBPC alone (2) Mean difference
Variables Mean (range) (£) Mean (range) (£) 1 minus 2 (£)
Occupied-bed days 4848 (4345-5530) 6221 (5135-8690) -1373
i.v. Antibiotics 467 (167-821) 666(0-2596) -199
i.v. Antifungals 23 (0-68) 35 (0-125) -12
i.v. Antiviral 39 (12-78) 185 (10-1489) -146
Platelet concentrates 504 (145-1088) 906 (145-2755) -402
RBC concentrates 157 (84-210) 207 (0-378) -50
G-CSF 462 (330-528) 96 (0-594) +366
Total costs 6500 (5465-8101) 8316 (5953-15801) -1816
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time to reach a granulocyte count of 0.5 x 109 1-1 was 9.7 days in
the G-CSF arm compared with 13.2 days in the control arm.
Similarly, the time to achieve a granulocyte count of 1.0 x 109 1-'
was 10.1 days in the G-CSF arm compared with 14.7 days in the
control arm. This represents an improvement of 2-5 days in
achieving a granulocyte count of0.5 x 109 1-l and an improvement
of 3-6 days in achieving a count of 1.0 x 109 1-l. Our recovery
periods were somewhat better overall compared with the studies
above, and it is tempting to speculate that this may be related to the
fact that our patients had PBPC collected early, before more
severe cytotoxic damage to bone marrow tissue had occurred. In
addition, we found that recovery periods in patients receiving
G-CSF were more predictable, with values clustering around the
mean value (-10 days) in contrast to patients in the control group
in which a significantly wider range of recovery time was seen. It
is of interest that the mean time for neutrophil recovery corre-
sponds to the minimum time required for myeloid lineage-
restricted progenitor cells that bear receptors for G-CSF to
differentiate into mature granulocytes (Peters et al, 1993).
The administration ofG-CSF was also associated with a statisti-
cally significant reduction in the median duration of stay in
hospital. Furthermore, the number of days in hospital were more
predictable in the G-CSF group (range 11-14 days) than in the
control group in which hospital stay varied between 13 and 22
days. It is not unreasonable to suggest, therefore, that administra-
tion of G-CSF in this setting might lead to better use of health
resources on the basis that the next patient can be prepared for
impending admission with greater confidence. More importantly,
the use of G-CSF was associated with an observed reduction of
hospital costs, despite the additional cost of G-CSF itself. This
difference, however, was not statistically significant, although
there was atrend in favour ofG-CSFusage (P = 0.06), and itwould
be interesting to explore whether, with a larger series of patients
and/or in a more expensive non-NHS health care system, this
difference becomes statistically significant. Nevertheless, even if
costs were the same, it can be argued that the G-CSF strategy
would be preferred because of the improved quality of life as a
result of reduced hospital stays and improved use of the available
bed resources. It may be possible to reduce the cost of G-CSF
further while maintaining its effectiveness by delaying the start of
G-CSF. Indeed, in a randomized study, Torres Gomez et al (1995)
showed that starting G-CSF at day +7 rather than day 0 did not
lead to a delay in granulocyte recovery and was associated with
significant cost reduction. In contrast to some studies (Shimazaki
et al, 1994; Klump et al, 1995; Colombat et al, 1996), we were not
able to show any statistically significant difference in the number
offebrile days ordocumented episodes ofbacteraemia. The lack of
any clinical benefit seen in terms of the rate of platelet recovery
and platelet/red cell transfusion requirements is not unexpected as
G-CSF has been shown to generate only granulopoiesis in experi-
mental studies (Metcalf and Nicola, 1983).
In this randomized study, the use of G-CSF after PBPC re-infu-
sion resulted in an improved rate of granulocyte recovery and a
more predictable and shorter hospital stay in patients with poor-
prognosis high-grade NHL treated with HDCT in first remission.
More importantly, and despite the additional costs ofusing G-CSF,
the clinical benefits observed were not associated with any
increased health care expenditure. Indeed, there was a trend
towards reduced expenditure, calculated in terms of occupied-bed
days, drugs, growth factor usage and blood products requirements.
We conclude that the use of G-CSF in this setting leads to an
improved outcome for the patient at no extra cost to the health
care system.
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